Search

A case report published in Reactions Weekly describes a middle-aged man who experienced lack of efficacy while being treated for dermatophytosis. The man had a widespread rash on his body and was initially treated with various medications including clobetasol, gentamicin, neomycin, terbinafine, clotrimazole, miconazole, prednisolone, and ciclosporin. Despite the treatment, his condition did not improve and continued to worsen. This case highlights the need for further research and alternative treatment options for dermatophytosis. [Extracted from the article]

A report describes two cases of patients who developed primary adrenal insufficiency (PAI) while receiving treatment with posaconazole for antifungal prophylaxis. One patient, a 35-year-old woman, had a history of myelodysplastic syndrome and underwent a stem-cell transplant. The other patient, a 62-year-old man, had myelodysplastic syndrome/myeloproliferative neoplasm and was treated with busulfan. Both patients experienced symptoms such as fatigue and low cortisol levels, and were diagnosed with PAI. Treatment with hydrocortisone improved their condition, and subsequent tests showed normal adrenal gland function. The woman continued to receive posaconazole, while the man discontinued posaconazole treatment. [Extracted from the article]

Insight Pharmaceuticals has issued a voluntary recall of two lots of TING 2% Miconazole Nitrate Athlete's Foot Spray Antifungal Spray Powder in the US due to elevated levels of benzene in the propellant. Benzene is a carcinogen that can potentially cause cancers such as leukemia and blood cancer. However, no serious adverse events related to this recall have been reported. The affected lots were distributed nationwide and consumers who have purchased the recalled product can receive reimbursement. It is advised to contact a healthcare provider if any problems are experienced with the use of this antifungal product. [Extracted from the article]

The table below provides a list of the drugs associated with non-serious adverse events identified in the scientific literature over the last week. Reactions Weekly 29 Jun 2022. [Extracted from the article]

He started receiving antifungal treatment with nystatin and sodium bicarbonate tablets and miconazole [miconazole nitrate] cream. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 63-year-old man exhibited lack of efficacy during treatment with miconazole, nystatin and sodium bicarbonate for chronic hyperplastic candidiasis [ I dosages and not all routes stated i ]. [Extracted from the article]

The table below provides a list of the drugs associated with non-serious adverse events identified in the scientific literature over the last week. Reactions Weekly 28 Jul 2021. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug interaction A man in his 70s [ I exact age not stated i ] developed pharyngeal haematoma and coagulopathy following concomitant administration of miconazole for oral candidiasis, and warfarin for anticoagulation [ I dosages not stated i ; I not all routes stated i ]. Based on this information, it was suspected that a pharmacokinetic interaction between warfarin and miconazole had led to reduced metabolism and clearance of warfarin, resulting in the development of pharyngeal haematoma and coagulopathy. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 50-year-old woman developed acute generalised exanthematous pustulosis (AGEP)/DRESS overlap during treatment with miconazole for oral candidiasis. Serologic tests revealed an EBV viral load of 1 254 copies/mL indicative of EBV reactivation. To exclude irritant contact dermatitis with miconazole, a skin biopsy was performed on the patch-test region which revealed spongiotic dermatitis consistent with allergic contact dermatitis, that confirmed the imputability of miconazole. [Extracted from the article]

The patients in the United-Kingdom started receiving an anticoagulation therapy with warfarin along with miconazole. The man's warfarin therapy was discontinued and his elevated INR was successfully treated with vitamin K. All the other patients were also successfully treated during brief hospitalisation. [Extracted from the article]

A 75-year-old man developed bruising and had increased INR during concomitant use of miconazole and warfarin [ I dosages not stated; not all routes, durations of treatments to reactions onsets and outcomes stated i ]. This presentation showed that the interaction between warfarin and miconazole boost the effects of the warfarin, which resulted in increased INR and bruising. B Author comment: b I "The interaction between [warfarin and miconazole] is well known to boost the effects of the warfarin by inhibiting its metabolism.". [Extracted from the article]

The number of systemic treatment courses ranged between 0-3, and weeks of treatment ranged between 0-53, with 1 patient being treated for >104 weeks. During the therapy, Trichophyton rubrum (12 patients) and Trichophyton interdigitale (2 patients) were identified on culture from the skin or nail specimen. Squalene epoxidase target gene sequencing revealed amino acid substitutions, such as H440Y/F484Y (1 patient), F397L (7 patients), L393S (2 patients), L393F (2 patients), F415S (1 patient) and I121M/V237I (1 patient). [Extracted from the article]

The article offers information on the report Drug Safety Update released by Great Britain's Medicines and Healthcare products Regulatory Agency (MHRA) on possible interaction between miconazole oral gel and warfarin leading to bleeding complications.

The article describes cases of Candida haemulonii infection that developed in 3 men, aged 52, 69 and 79 years, following the topical application of miconazole cream on chronic leg ulcers.

The article focuses on the move of New Zealand Medicines and Medical Devices Safety Authority to seek information concerning proposed label warnings on topical over-the-counter miconazole-containing products about interactions with warfarin.

The article describes cases of four patients who developed loss of coagulation control following concomitant use of phenprocoumon or acenocoumarol and topical miconazole.

An abstract of the article "Prolonged effects of miconazole oral gel on warfarin anticoagulation even after treatment withdrawal" by S. Murakami and others is presented.

The article focuses on the further measures being considered by the Great Britain Medicines and Healthcare Products Regulatory Agency (MHRA) for the reduction of the risk of miconazole and warfarin interactions.

The article presents a case study of a 68-year-old man who developed elevated INR and bruising during concomitant administration of miconazole, metronidazole and warfarin.

The article discusses the Danish Medicines Agency's (DKMA) report which cited the need for doctors and dentists to increase the awareness of phamacokinetic interactions between warfarin, an anticoagulant and miconazole

The article describes a case of tinea incognito induced by pimecrolimus treatment in a 58-year-old man with a pruritic, symmetrical erythematous eruption. The patient self-administer topical pimecrolimus cream twice daily to relieve his pruritus. It describes the lesions developed by the man, two weeks following pimecrolimus use. His lesions resolved through itraconazole and miconazole treatment.

The article presents a case study of a 79-year-old male patient who developed a bleeding complication following co-administration of rivaroxaban and miconazole for treatment of ischaemic heart disease and atrial flutter.

The article discusses a study published in the 2014 issue of "Tunisie Medicale" that reported a case of a 55-year-old man who developed genital fixed drug eruption following administration of miconazole.

The article presents a case study of a 79-year-old man with aphagia caused by aphthous stomatitis and developed increased anticoagulant activity of fluidione while receiving miconazole.

An abstract of the article "Warfarin and topical miconazole: The potential for a clinically significant interaction," by C. C. Ufondu and colleagues is presented.

The article describes a case of elevated International Normalized Ratio (INR) during treatment with intravaginal miconazole for candidiasis in a 50-year-old woman who was receiving warfarin for prevention of deep vein thrombosis.

The article reports on the case of a 55-year-old man who developed a circular, erythematous, oedematous eruption on his glans penis when he was treated for an oral fungal infection with miconazole gel. The patient developed new lesions at the same site as well as lesions at other sites on his glans penis when he was exposed again to miconazole gel in April 2009.

The article describes the case of a woman who developed allergic contact dermatitis to miconazole that was exacerbated by ketoconazole. She presented with a history of chronic itching and increased dandruff, and, examination revealed erythema and scales all over her scalp. She was diagnosed with seborrhoeic dermatitis and prescribed ketoconazole lotion. A contact allergy to the ketoconazole was suspected and the miconazole shampoo was discontinued.

The article describes the case of a 78-year-old woman who acquired oral osteonecrosis. The patient developed the said condition while undergoing treatment with ibandronic acid. She was given various drugs including clindamycin, miconazole oral gel and chlorhexidine. She will continue taking oral ibandronic acid.

The article considers the warning of Finland's National Agency for Medicines (NAM) regarding the use of miconazole or Daktarin oral gel in patients receiving warfarin. According to NAM the use of the oral gel may lead to increased International Normalized Ratio (INR) level. The article summarizes two case studies associated with the use of warfarin for auricular fibrillation and Daktarin oral gel.